COSCIENS Biopharma Inc 6-K, filed May 20, 2026
COSCIENS Biopharma Inc. (CSCIF)
About this 6-K
COSCIENS Biopharma Inc filed this 6-K on May 20, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2026
Commission File Number: 001-38064
COSCIENS Biopharma Inc.
(Translation of registrant’s name into English)
c/o Borden Ladner Gervais, LLP
22 Adelaide St. West, Suite 3400
Bay Adelaide Centre, East Tower
Toronto ON M5H 4E3
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
The board of directors of COSCIENS Biopharma Inc. (the “Company”) passed a resolution to convene a Special Meeting of Shareholders and Management Proxy Circular (the “Circular”) of the Company on June 17, 2026 at 9:30 am (Eastern time).
On or before May 21, 2026, the shareholders of the Company were sent a notice of the Circular and a form of proxy.
DOCUMENTS INDEX
| Exhibit | Description | |
| 99.1 | Notice of Annual and Special Meeting of Shareholders and Management Proxy Circular, dated May 18, 2026. | |
| 99.2 | Form of Proxy. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| COSCIENS Biopharma Inc. | ||
| Date: May 20, 2026 | By: | /s/ Giuliano La Fratta |
| Name: Giuliano La Fratta | ||
| Title: Chief Financial Officer | ||
Exhibit 99.1
Exhibit 99.2
